Home > Insider Trading > Filing (0001209191-16-130277)

Filing Details

Accession Number:: 0001209191-16-130277
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-30 18:01:19
Reporting Period:: 2016-06-28

Filing Date:: 2016-06-30
Accepted Time:: 2016-06-30 18:01:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1311596	Tobira Therapeutics Inc.	TBRA	Pharmaceutical Preparations (2834)	030422069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1388325	A/S Novo	Tuborg Havnevej 19 Hellerup G7 2900		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2016-06-28	20,883	$13.77	2,073,022	No	4	S	Direct
Common Stock	Disposition	2016-06-28	2,730	$14.28	2,070,292	No	4	S	Direct
Common Stock	Disposition	2016-06-29	16,068	$12.63	2,054,224	No	4	S	Direct
Common Stock	Disposition	2016-06-30	27,133	$12.58	2,027,091	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.01 to $14.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.50 to $13.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.50 to $12.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.